Amplyx - Articles and news items

Amplyx initiates dosing in antifungal Phase I trial for the treatment of life-threatening infections

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

APX001 is a small molecule drug candidate that targets and inhibits the conserved fungal enzyme Gwt1, compromising fungal growth of major fungal pathogens…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+